Overview

Rosuvastatin in the Treatment of Rectal Cancer

Status:
Unknown status

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

This study will evaluate whether the addition of Rosuvastatin to standard chemoradiation therapy for the treatment of locally advanced rectal cancer may improve the pathological response rate and survival compared to standard chemoradiation therapy alone.

Phase:

Phase 2

Details

Lead Sponsor:

AHS Cancer Control Alberta

Collaborator:

Ozmosis Research Inc.

Treatments:

Rosuvastatin Calcium